Epalrestat is a drug that restricts aldose reductase enzyme which catalyzes the transformation of glucose to sorbitol. Increased sorbitol levels in some cells occur in states of hyperglycemia and bring about hyperosmotic impacts which might be associated with diabetic complications. Aldose reductase inhibitors have no impact on blood glucose levels.
This medicine lessens intracellular sorbitol accumulation significantly. There can be improvements in nerve function once a diabetic is treated with this medicine. Epalrestat is not advisable to be used in people who have hypersensitivity, which is a contraindication. If you have hepatic insufficiency, this medicine may not be for you. If you are breastfeeding or pregnant, visit a doctor to know whether the medicine is for you.
Side effects may include vomiting, nausea, and abnormal liver functioning. If these side effects become serious, consult a doctor for immediate attention. Long – term treatment with epalrestat can effectively delay the progression of diabetic neuropathy and ameliorate the symptoms of the disease, specifically in people with good glycemic control and limited microangiopathy.